Table A3.

PRO Score Changes Compared With Baseline by Treatment Arm

PRO/Baseline Time Point	Tamoxifen Alone			Tamoxifen + OFS			P (t test)
	No. of Participants	Mean	SD	No. of Participants	Mean	SD
FACT-B
Month 6	94	−0.09	14.82	84	−0.02	14.40	.97
Year 1	88	0.43	14.56	86	−1.27	15.36	.45
Year 2	70	0.82	15.03	72	0.64	14.02	.94
Year 3	69	4.06	14.72	68	0.00	18.38	.16
Year 4	66	1.90	15.71	66	0.05	17.61	.53
Year 5	64	1.88	16.05	52	5.30	15.36	.25
FACT-G
Month 6	144	1.20	11.74	137	−0.12	11.87	.35
Year 1	132	1.96	12.00	135	−1.04	11.40	.038
Year 2	114	2.56	12.71	123	0.73	12.62	.27
Year 3	101	5.51	11.69	111	1.15	14.19	.016
Year 4	103	3.49	13.69	103	1.13	13.06	.21
Year 5	95	3.94	13.35	89	2.44	13.05	.44
Breast subscale
Month 6	95	−0.45	4.87	85	−0.25	5.19	.80
Year 1	89	−0.36	5.27	86	−0.79	5.94	.61
Year 2	70	−0.75	4.54	72	−1.24	5.58	.57
Year 3	69	−0.14	5.01	68	−0.88	6.69	.47
Year 4	66	−0.80	4.70	66	−0.99	5.86	.83
Year 5	66	−0.97	5.95	53	1.47	6.36	.033
Menopausal symptoms
Month 6	126	−5.24	8.19	123	−8.90	9.05	.001
Year 1	119	−4.80	8.20	129	−9.72	9.03	< .001
Year 2	105	−5.60	8.70	115	−9.57	9.69	.002
Year 3	89	−4.13	9.47	107	−9.23	9.40	< .001
Year 4	95	−5.71	9.32	99	−9.00	9.46	.016
Year 5	90	−4.46	9.56	84	−7.71	10.20	.031
Sexual function
Month 6	99	−1.67	3.81	105	−2.99	4.03	.017
Year 1	99	−1.92	3.95	113	−3.29	4.29	.017
Year 2	87	−2.23	4.62	99	−4.47	5.07	.002
Year 3	73	−2.22	4.33	95	−4.73	4.91	.001
Year 4	73	−3.04	4.72	79	−4.78	5.55	.041
Year 5	72	−3.06	4.90	69	−4.86	5.09	.034

Abbreviation: FACT-B, Functional Assessment of Cancer Therapy-Breast; FACT-G, FACT-General; PRO, patient-reported outcome; SD, standard deviation.